APO Research
Talk to an analyst

APO RESEARCH · REPORT

Adeno-Associated Virus (AAV) Gene Therapy

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Adeno-Associated Virus (AAV) Gene Therapy Industry Growth and Trends Forecast to 2032

12 August 2026112 pages

Choose your research edition.

Industry ResearchAdeno-Associated Virus (AAV) Gene Therapy Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Adeno-Associated Virus (AAV) Gene Therapy Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Adeno-Associated Virus (AAV) Gene Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adeno-Associated Virus (AAV) Gene Therapy Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Adeno-Associated Virus (AAV) Gene Therapy Market Analysis and Forecast 2026-2032186 pages · $4,950 USD

Market perspective

According to APO Research, the global Adeno-Associated Virus (AAV) Gene Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Adeno-Associated Virus (AAV) Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Adeno-Associated Virus (AAV) Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Adeno-Associated Virus (AAV) Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Adeno-Associated Virus (AAV) Gene Therapy market include AGC Biologics, StrideBio, SIRION Biotech, Neurophth Biotechnology, Belief BioMed, BiBo Biopharma Engineering Co., LTD., Beihai Kangcheng, PackGene Biotech and Sarepta Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Adeno-Associated Virus (AAV) Gene Therapy market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Adeno-Associated Virus (AAV) Gene Therapy market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Adeno-Associated Virus (AAV) Gene Therapy market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Adeno-Associated Virus (AAV) Gene Therapy.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Adeno-Associated Virus (AAV) Gene Therapy market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Adeno-Associated Virus (AAV) Gene Therapy Market by Company

AGC Biologics

StrideBio

SIRION Biotech

Neurophth Biotechnology

Belief BioMed

BiBo Biopharma Engineering Co., LTD.

Beihai Kangcheng

PackGene Biotech

Sarepta Therapeutics

Carbon BioSciences

Kelonia Therapeutics

Roche

Remedium Bio

Creative Biolabs

Affinia Therapeutics

Spark Therapeutics

Adeno-Associated Virus (AAV) Gene Therapy Segment by Type

Luxturna

Zolgensma

Others

Adeno-Associated Virus (AAV) Gene Therapy Segment by Application

Central Nervous System Diseases

Ocular Diseases

Liver-directed Diseases

Other Hereditary Diseases

Adeno-Associated Virus (AAV) Gene Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adeno-Associated Virus (AAV) Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adeno-Associated Virus (AAV) Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adeno-Associated Virus (AAV) Gene Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Adeno-Associated Virus (AAV) Gene Therapy companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share by Region (2021-2026) Table 4. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share by Region (2027-2032) Table 6. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Share by Type (2021-2026) Table 9. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Share Forecasted by Type (2027-2032) Table 11. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Share by Application (2021-2026) Table 24. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Share Forecasted by Application (2027-2032) Table 26. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Adeno-Associated Virus (AAV) Gene Therapy Industry Trends Table 37. Adeno-Associated Virus (AAV) Gene Therapy Industry Drivers Table 38. Adeno-Associated Virus (AAV) Gene Therapy Industry Opportunities and Challenges Table 39. Adeno-Associated Virus (AAV) Gene Therapy Industry Restraints Table 40. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Market Share by Company (2021-2026) Table 42. Global Adeno-Associated Virus (AAV) Gene Therapy Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Adeno-Associated Virus (AAV) Gene Therapy Key Company Headquarters & Area Served Table 44. Global Adeno-Associated Virus (AAV) Gene Therapy Company, Product Type & Application Table 45. Global Adeno-Associated Virus (AAV) Gene Therapy Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Adeno-Associated Virus (AAV) Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. AGC Biologics Company Information Table 49. AGC Biologics Business Overview Table 50. AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 52. AGC Biologics Recent Development Table 53. StrideBio Company Information Table 54. StrideBio Business Overview Table 55. StrideBio Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. StrideBio Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 57. StrideBio Recent Development Table 58. SIRION Biotech Company Information Table 59. SIRION Biotech Business Overview Table 60. SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 62. SIRION Biotech Recent Development Table 63. Neurophth Biotechnology Company Information Table 64. Neurophth Biotechnology Business Overview Table 65. Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 67. Neurophth Biotechnology Recent Development Table 68. Belief BioMed Company Information Table 69. Belief BioMed Business Overview Table 70. Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 72. Belief BioMed Recent Development Table 73. BiBo Biopharma Engineering Co., LTD. Company Information Table 74. BiBo Biopharma Engineering Co., LTD. Business Overview Table 75. BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 77. BiBo Biopharma Engineering Co., LTD. Recent Development Table 78. Beihai Kangcheng Company Information Table 79. Beihai Kangcheng Business Overview Table 80. Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 82. Beihai Kangcheng Recent Development Table 83. PackGene Biotech Company Information Table 84. PackGene Biotech Business Overview Table 85. PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 87. PackGene Biotech Recent Development Table 88. Sarepta Therapeutics Company Information Table 89. Sarepta Therapeutics Business Overview Table 90. Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 92. Sarepta Therapeutics Recent Development Table 93. Carbon BioSciences Company Information Table 94. Carbon BioSciences Business Overview Table 95. Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 97. Carbon BioSciences Recent Development Table 98. Kelonia Therapeutics Company Information Table 99. Kelonia Therapeutics Business Overview Table 100. Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 102. Kelonia Therapeutics Recent Development Table 103. Roche Company Information Table 104. Roche Business Overview Table 105. Roche Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Roche Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 107. Roche Recent Development Table 108. Remedium Bio Company Information Table 109. Remedium Bio Business Overview Table 110. Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 112. Remedium Bio Recent Development Table 113. Creative Biolabs Company Information Table 114. Creative Biolabs Business Overview Table 115. Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 117. Creative Biolabs Recent Development Table 118. Affinia Therapeutics Company Information Table 119. Affinia Therapeutics Business Overview Table 120. Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 122. Affinia Therapeutics Recent Development Table 123. Spark Therapeutics Company Information Table 124. Spark Therapeutics Business Overview Table 125. Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio Table 127. Spark Therapeutics Recent Development Table 128. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026) & (US$ Million) Table 130. North America Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country (2021-2026) Table 131. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. North America Adeno-Associated Virus (AAV) Gene Therapy Market Share Forecast by Country (2027-2032) Table 133. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026) & (US$ Million) Table 135. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country (2021-2026) Table 136. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Share Forecast by Country (2027-2032) Table 138. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026) & (US$ Million) Table 140. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country (2021-2026) Table 141. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Share Forecast by Country (2027-2032) Table 143. Latin America Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Latin America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026) & (US$ Million) Table 145. Latin America Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country (2021-2026) Table 146. Latin America Adeno-Associated Virus (AAV) Gene Therapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Latin America Adeno-Associated Virus (AAV) Gene Therapy Market Share Forecast by Country (2027-2032) Table 148. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026) & (US$ Million) Table 150. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country (2021-2026) Table 151. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Share Forecast by Country (2027-2032) Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Adeno-Associated Virus (AAV) Gene Therapy Product Image Figure 3. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 5. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share by Region: 2025 VS 2032 Figure 6. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share by Region (2021-2032) Figure 7. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Luxturna Image Figure 13. Global Luxturna Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Zolgensma Image Figure 15. Global Zolgensma Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Others Image Figure 17. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Overview by Type (2021-2032) & (US$ Million) Figure 19. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share by Type 2025 VS 2032 Figure 20. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size Share by Type (2021-2032) Figure 21. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size Share by Type (2021-2032) Figure 22. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size Share by Type (2021-2032) Figure 23. Latin America Adeno-Associated Virus (AAV) Gene Therapy Market Size Share by Type (2021-2032) Figure 24. Middle East and Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size Share by Type (2021-2032) Figure 25. Central Nervous System Diseases Image Figure 26. Global Central Nervous System Diseases Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Ocular Diseases Image Figure 28. Global Ocular Diseases Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Liver-directed Diseases Image Figure 30. Global Liver-directed Diseases Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Other Hereditary Diseases Image Figure 32. Global Other Hereditary Diseases Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share by Application 2025 VS 2032 Figure 35. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size Share by Application (2021-2032) Figure 36. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size Share by Application (2021-2032) Figure 37. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size Share by Application (2021-2032) Figure 38. Latin America Adeno-Associated Virus (AAV) Gene Therapy Market Size Share by Application (2021-2032) Figure 39. Middle East and Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size Share by Application (2021-2032) Figure 40. Global Top 5 and 10 Adeno-Associated Virus (AAV) Gene Therapy Players Market Share by Revenue in 2025 Figure 41. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 42. North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. North America Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. North America Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country (2021-2032) Figure 45. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country (2021-2032) Figure 48. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country (2021-2032) Figure 51. Latin America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Latin America Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country (2021-2032) Figure 54. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Share by Country (2021-2032) Figure 57. Years Considered Figure 58. Research Process Figure 59. Key Executives Interviewed

Scope & coverage.

Types
  • Luxturna
  • Zolgensma
  • Others
Applications
  • Central Nervous System Diseases
  • Ocular Diseases
  • Liver-directed Diseases
  • Other Hereditary Diseases
Companies covered
  • AGC Biologics
  • StrideBio
  • SIRION Biotech
  • Neurophth Biotechnology
  • Belief BioMed
  • BiBo Biopharma Engineering Co., LTD.
  • Beihai Kangcheng
  • PackGene Biotech
  • Sarepta Therapeutics
  • Carbon BioSciences
  • Kelonia Therapeutics
  • Roche
  • Remedium Bio
  • Creative Biolabs
  • Affinia Therapeutics
  • Spark Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region (2021-2032)
  5. 1.4.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region (2021-2026)
  6. 1.4.2 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region (2027-2032)
  7. 1.5 Key Regions Adeno-Associated Virus (AAV) Gene Therapy Market Size (2021-2032)
  8. 1.5.1 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (2021-2032)
2 Adeno-Associated Virus (AAV) Gene Therapy Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Luxturna
  3. 2.1.2 Zolgensma
  4. 2.1.3 Others
  5. 2.2 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type
  6. 2.2.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Overview by Type (2021-2032)
  7. 2.2.2 Global Adeno-Associated Virus (AAV) Gene Therapy Historic Market Size Review by Type (2021-2026)
  8. 2.2.3 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Forecasted by Type (2027-2032)
  9. 2.3 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Regions
  10. 2.3.1 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Type (2021-2026)
  11. 2.3.2 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Type (2021-2026)
  12. 2.3.3 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Type (2021-2026)
  13. 2.3.4 South America Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Type (2021-2026)
  14. 2.3.5 Middle East and Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Type (2021-2026)
3 Adeno-Associated Virus (AAV) Gene Therapy Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Central Nervous System Diseases
  3. 3.1.2 Ocular Diseases
  4. 3.1.3 Liver-directed Diseases
  5. 3.1.4 Other Hereditary Diseases
  6. 3.2 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application
  7. 3.2.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Overview by Application (2021-2032)
  8. 3.2.2 Global Adeno-Associated Virus (AAV) Gene Therapy Historic Market Size Review by Application (2021-2026)
  9. 3.2.3 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size Forecasted by Application (2027-2032)
  10. 3.3 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Regions
  11. 3.3.1 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Application (2021-2026)
  12. 3.3.2 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Application (2021-2026)
  13. 3.3.3 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Application (2021-2026)
  14. 3.3.4 South America Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Application (2021-2026)
  15. 3.3.5 Middle East and Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Adeno-Associated Virus (AAV) Gene Therapy Industry Trends
  2. 4.2 Adeno-Associated Virus (AAV) Gene Therapy Industry Drivers
  3. 4.3 Adeno-Associated Virus (AAV) Gene Therapy Industry Opportunities and Challenges
  4. 4.4 Adeno-Associated Virus (AAV) Gene Therapy Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Adeno-Associated Virus (AAV) Gene Therapy Revenue (2021-2026)
  2. 5.2 Global Adeno-Associated Virus (AAV) Gene Therapy Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Adeno-Associated Virus (AAV) Gene Therapy Key Company Headquarters & Area Served
  4. 5.4 Global Adeno-Associated Virus (AAV) Gene Therapy Company, Product Type & Application
  5. 5.5 Global Adeno-Associated Virus (AAV) Gene Therapy Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Adeno-Associated Virus (AAV) Gene Therapy Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Adeno-Associated Virus (AAV) Gene Therapy Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 AGC Biologics
  2. 6.1.1 AGC Biologics Company Information
  3. 6.1.2 AGC Biologics Business Overview
  4. 6.1.3 AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  6. 6.1.5 AGC Biologics Recent Developments
  7. 6.2 StrideBio
  8. 6.2.1 StrideBio Company Information
  9. 6.2.2 StrideBio Business Overview
  10. 6.2.3 StrideBio Adeno-Associated Virus (AAV) Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 StrideBio Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  12. 6.2.5 StrideBio Recent Developments
  13. 6.3 SIRION Biotech
  14. 6.3.1 SIRION Biotech Company Information
  15. 6.3.2 SIRION Biotech Business Overview
  16. 6.3.3 SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  18. 6.3.5 SIRION Biotech Recent Developments
  19. 6.4 Neurophth Biotechnology
  20. 6.4.1 Neurophth Biotechnology Company Information
  21. 6.4.2 Neurophth Biotechnology Business Overview
  22. 6.4.3 Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  24. 6.4.5 Neurophth Biotechnology Recent Developments
  25. 6.5 Belief BioMed
  26. 6.5.1 Belief BioMed Company Information
  27. 6.5.2 Belief BioMed Business Overview
  28. 6.5.3 Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  30. 6.5.5 Belief BioMed Recent Developments
  31. 6.6 BiBo Biopharma Engineering Co., LTD.
  32. 6.6.1 BiBo Biopharma Engineering Co., LTD. Company Information
  33. 6.6.2 BiBo Biopharma Engineering Co., LTD. Business Overview
  34. 6.6.3 BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  36. 6.6.5 BiBo Biopharma Engineering Co., LTD. Recent Developments
  37. 6.7 Beihai Kangcheng
  38. 6.7.1 Beihai Kangcheng Company Information
  39. 6.7.2 Beihai Kangcheng Business Overview
  40. 6.7.3 Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  42. 6.7.5 Beihai Kangcheng Recent Developments
  43. 6.8 PackGene Biotech
  44. 6.8.1 PackGene Biotech Company Information
  45. 6.8.2 PackGene Biotech Business Overview
  46. 6.8.3 PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  48. 6.8.5 PackGene Biotech Recent Developments
  49. 6.9 Sarepta Therapeutics
  50. 6.9.1 Sarepta Therapeutics Company Information
  51. 6.9.2 Sarepta Therapeutics Business Overview
  52. 6.9.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  54. 6.9.5 Sarepta Therapeutics Recent Developments
  55. 6.10 Carbon BioSciences
  56. 6.10.1 Carbon BioSciences Company Information
  57. 6.10.2 Carbon BioSciences Business Overview
  58. 6.10.3 Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  60. 6.10.5 Carbon BioSciences Recent Developments
  61. 6.11 Kelonia Therapeutics
  62. 6.11.1 Kelonia Therapeutics Company Information
  63. 6.11.2 Kelonia Therapeutics Business Overview
  64. 6.11.3 Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  66. 6.11.5 Kelonia Therapeutics Recent Developments
  67. 6.12 Roche
  68. 6.12.1 Roche Company Information
  69. 6.12.2 Roche Business Overview
  70. 6.12.3 Roche Adeno-Associated Virus (AAV) Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Roche Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  72. 6.12.5 Roche Recent Developments
  73. 6.13 Remedium Bio
  74. 6.13.1 Remedium Bio Company Information
  75. 6.13.2 Remedium Bio Business Overview
  76. 6.13.3 Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  78. 6.13.5 Remedium Bio Recent Developments
  79. 6.14 Creative Biolabs
  80. 6.14.1 Creative Biolabs Company Information
  81. 6.14.2 Creative Biolabs Business Overview
  82. 6.14.3 Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  84. 6.14.5 Creative Biolabs Recent Developments
  85. 6.15 Affinia Therapeutics
  86. 6.15.1 Affinia Therapeutics Company Information
  87. 6.15.2 Affinia Therapeutics Business Overview
  88. 6.15.3 Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  90. 6.15.5 Affinia Therapeutics Recent Developments
  91. 6.16 Spark Therapeutics
  92. 6.16.1 Spark Therapeutics Company Information
  93. 6.16.2 Spark Therapeutics Business Overview
  94. 6.16.3 Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product Portfolio
  96. 6.16.5 Spark Therapeutics Recent Developments
7 North America
  1. 7.1 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026)
  3. 7.3 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026)
  3. 8.3 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026)
  3. 10.3 South America Adeno-Associated Virus (AAV) Gene Therapy Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst